IRadimed Price Target Cut to $60.00/Share From $65.00 by Roth MKM
IRadimed Analyst Ratings
Lake Street Maintains IRadimed(IRMD.US) With Buy Rating, Maintains Target Price $60
Iradimed (IRMD) Gets a Buy From Roth MKM
Roth MKM Maintains IRadimed(IRMD.US) With Buy Rating, Cuts Target Price to $60
Lake Street Maintains IRadimed(IRMD.US) With Buy Rating, Maintains Target Price $60
Lake Street Maintains IRadimed(IRMD.US) With Buy Rating, Maintains Target Price $60
Lake Street Maintains IRadimed(IRMD.US) With Buy Rating, Maintains Target Price $60
Lake Street Maintains IRadimed(IRMD.US) With Buy Rating, Maintains Target Price $60
Lake Street Remains a Buy on Iradimed (IRMD)
Iradimed (IRMD) Gets a Buy From Lake Street
Roth MKM: Reiterates iRadimed (IRMD.US) buy rating with a target price of $65.00.
IRadimed Analyst Ratings
Roth MKM Reinstates Buy on IRadimed, Announces $65 Price Target
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Iradimed (IRMD)
Lake Street Reaffirms Their Buy Rating on Iradimed (IRMD)
Analysts Conflicted on These Healthcare Names: Iradimed (IRMD), Harmony Biosciences Holdings (HRMY) and Pfizer (PFE)
Lake Street Keeps Their Buy Rating on Iradimed (IRMD)
Iradimed (IRMD) Receives a Buy From Lake Street